Abstract
Although surgical resection of localized renal cell carcinoma (RCC) can be curative for localized disease, some patients may relapse. In addition, RCCs can be clinically silent during their course, and the initial diagnosis can be delayed until disease is either locally advanced and unresectable or metastatic. The natural history of disease for patients with advanced or metastatic RCC can widely be different from few months to many years depending on the clinical, pathologic, laboratory, and radiographic features of disease, as well as therapy response. The understanding of the molecular pathogenesis of RCC allowed to identify targets for therapeutic intervention with the development of multiple agents, having an important role in the management of patients with advanced disease. Among them, antiangiogenic drugs have changed the management of these patients considering the central role of angiogenesis in the metastatic RCC tumorigenesis and progression. In this chapter, an overview on the use of antiangiogenic drugs in the treatment of RCC, with regard to their chemosensitizer aspect, is provided.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
